Skip to main navigation Skip to search Skip to main content

Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1α in Prostate Cancer Cells

  • Kuntal Biswas
  • , Sukumar Sarkar
  • , Neveen Said
  • , David L Brautigan
  • , James M Larner

Research output: Contribution to journalArticlepeer-review

Abstract

Hypoxia is a major factor in tumor progression and resistance to therapies, which involves elevated levels of the transcription factor HIF1α. Here, we report that prostate tumor xenografts express high levels of HIF1α and show greatly enhanced growth in response to knockdown of the E3 ligase CHIP (C-terminus of Hsp70-interacting protein). In multiple human prostate cancer cell lines under hypoxia, taxol treatment induces the degradation of HIF1α, and this response is abrogated by knockdown of CHIP, but not by E3 ligase VHL or RACK1. HIF1α degradation is accompanied by loss of function, evidenced by reduced expression of HIF1α-dependent genes. CHIP-dependent HIF1α degradation also occurs in cells arrested in mitosis by nocodazole instead of taxol. Mitotic kinase Aurora B activity is required for taxol-induced HIF1α degradation. Purified Aurora B directly phosphorylates HIF1α at multiple sites, and these modifications enhance its polyubiquitination by CHIP in a purified reconstituted system. Our results show how activation of Aurora B promotes CHIP-dependent degradation of HIF1α in prostate cancer cells. This new knowledge may affect the use of mitotic kinase inhibitors and open new approaches for treatment of hypoxic prostate tumors.

Original languageEnglish
Pages (from-to)1008-1017
Number of pages10
JournalMolecular cancer therapeutics
Volume19
Issue number4
DOIs
StatePublished - Apr 2020
Externally publishedYes

Keywords

  • Apoptosis
  • Aurora Kinase B/genetics
  • Biomarkers, Tumor/genetics
  • Cell Proliferation
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit/genetics
  • Male
  • Paclitaxel/pharmacology
  • Phosphorylation
  • Prostatic Neoplasms/drug therapy
  • Proteolysis
  • Tumor Cells, Cultured
  • Ubiquitin-Protein Ligases/genetics
  • Ubiquitination

Cite this